Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT02585713
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose supportive care
- Phase
- Phase 3
- Enrolled
- 300 participants
- Registry
-
NCT02585713
-
- Other papers using this trial's data
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02585713. Randomized; no masking; primary purpose supportive care. Start 2015-11-20 (actual); primary completion 2018-04-02 (actual). Results posted on 2019-12-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
- Condition
- Cerebral Vein Thrombosis
- Condition
- Deep Vein Thrombosis
- Condition
- Gonadal Thrombosis
- Condition
- Hepatic Thrombosis
- Condition
- Malignant Neoplasm
- Condition
- Mesenteric Thrombosis
- Condition
- Metastatic Malignant Neoplasm
- Condition
- Portal Vein Thrombosis
- Condition
- Pulmonary Embolism
- Condition
- Renal Vein Thrombosis
- Condition
- Splenic Thrombosis
- Condition
- Venous Thromboembolism
- Intervention (Drug)
- Apixaban
- Intervention (Drug)
- Dalteparin
- Intervention (Other)
- Questionnaire Administration
- Lead sponsor
- Academic and Community Cancer Research United
- Collaborator
- National Cancer Institute (NCI)
Record details
- Record id
cardio:ct-nct02585713- Content hash
6a93df9db0150237032ca6291ec02ea06eeafd39fa44a1c34e0f405d0878180d